The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Proteasome Inhibition Measurements: Clinical Application
Abstract
Background: PS-341, a selective inhibitor of the proteasome, currently is under evaluation as an anticancer agent in multiple phase I clinical trials. In animal-model studies, PS-341 was rapidly removed from the vascular compartment and distributed widely, quickly approaching the limits of detection. An accurate pharmacodynamic assay has been developed as an alternative or complement to pharmacokinetic measurements. Methods: Fluorogenic kinetic assays for both the chymotryptic and tryptic activities of the proteasome have been optimized for both whole blood and blood cells. Using the ratio of these activities and the catalytic mechanism of the proteasome, we developed a novel method of calculating percentage of inhibition, using two structurally unrelated inhibitors (PS-341 and lactacystin). Results: This ratio method was demonstrated to be sensitive (detection limit of 13% inhibition with 10 μg of cell lysate), specific to the proteasome (PS-341 provides >98% inhibition), accurate (112% analyte recovery), and precise (0% ± 5% inhibition at 0 nmol/L PS-341 and 74.5% ± 1.7% inhibition at 200 nmol/L PS-341). Using these assays, we found that both erythrocytes and leukocytes contain proteasome at 3 μmol/L. Pharmacodynamic results for PS-341 obtained from the whole-blood ratio method were comparable to those using leukocytes determined by another method. Conclusions: The described assay provides a reliable method for studying the pharmacodynamics of proteasome inhibitors and is now in use in concurrent phase I clinical trials with PS-341.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enzyme kinetics; behavior and analysis of rapid equilibrium and steady state enzyme systems
(1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90021-3 · Cited by 2,972
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Self-citationThe ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Self-citationThe Proteasome, a Novel Protease Regulated by Multiple Mechanisms
DeMartino, G. N., & Slaughter, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22123 · Cited by 530
Lactacystin, Proteasome Function, and Cell Fate
Fenteany, G., & Schreiber, S. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.15.8545 · Cited by 410
Tanaka, K., Ii, K., Ichihara, A., Waxman, L., & Goldberg, A. L. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66853-x · Cited by 324
Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis
Palombella, V. J., Conner, E. M., Fuseler, J. W., Destree, A., Davis, J. M., Laroux, F. S., Wolf, R. E., Huang, J., Brand, S., Elliott, P. J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15671 · Cited by 287
Self-citationUbiquitin and the Biology of the Cell
(1998) · Springer eBooks · doi:10.1007/978-1-4899-1922-9 · Cited by 271
Subcellular Localization, Stoichiometry, and Protein Levels of 26 S Proteasome Subunits in Yeast
Russell, S. J., Steger, K. A., & Johnston, S. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21943 · Cited by 194
Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells.
Kanayama, H., Tanaka, K., Aki, M., Kagawa, S., Miyaji, H., Satoh, M., Okada, F., Sato, S., Shimbara, N., & Ichihara, A. (1991) · PubMed · Cited by 163
Purification and characterization of a protein inhibitor of the 20S proteasome (macropain)
Chu-Ping, M., Slaughter, C. A., & Demartino, G. (1992) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(92)90218-3 · Cited by 142
Bone, R. F., Shenvi, A. B., Kettner, C. A., & Agard, D. A. (1987) · Biochemistry · doi:10.1021/bi00398a012 · Cited by 142
Kinetic Characterization of the Chymotryptic Activity of the 20S Proteasome
Stein, R. L., Melandri, F. D., & Dick, L. R. (1996) · Biochemistry · doi:10.1021/bi952262x · Cited by 138
Proteasome inhibition: A novel mechanism to combat asthma☆☆☆
Elliott, P. J., Pien, C. S., McCormack, T. A., Chapman, I. D., & Adams, J. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70369-6 · Cited by 111
Self-citationSegel, G., Cokelet, G., & Lichtman, M. A. (1981) · Blood · doi:10.1182/blood.v57.5.894.894 · Cited by 103
Bone, R. F., Frank, D., Kettner, C. A., & Agard, D. A. (1989) · Biochemistry · doi:10.1021/bi00445a015 · Cited by 88
Tsubuki, S., Saito, Y., & Kawashima, S. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00388-2 · Cited by 72
Lymphocyte response to phytohemagglutinin: Intracellular volume and intracellular [K+]
Holian, A., DEUTSCH, C. J., Holian, S. K., et al. (1979) · Journal of Cellular Physiology · doi:10.1002/jcp.1040980115 · Cited by 34
Cited by
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Self-citationChauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
Adams, J., & Kauffman, M. (2004) · Cancer Investigation · doi:10.1081/cnv-120030218 · Cited by 654
Self-citationEvaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2766 · Cited by 499
Metadata
- Authors
- Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., & Elliott, P. J.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-05-01
- Volume
- 46
- Issue
- 5
- Pages
- 673-683
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W1935443268
- Cited by
- 301
- References
- 19
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.